+Author Affiliation
s1Centre for Asthma and Respiratory Diseases, University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia. 2Dept of Allergy, Kaiser Permanente Medical Center, San Diego, CA, USA. V.E. Murphy, Centre for Asthma and Respiratory Diseases, Level 2, West Wing, Hunter Medical Research Institute, University of Newcastle, University Drive, Callaghan, NSW 2308, Australia. E-mail: vanessa.murphy@newcastle.edu.au
Abstract
Asthma commonly occurs in pregnant females, and recent data have outlined the risks of adverse perinatal outcomes among this population. There is an increased risk of low birth weight and small for gestational age, particularly among females with moderate-to-severe asthma and exacerbations during pregnancy. There is also an increased risk of preterm birth, especially with oral steroid use, a small but statistically significant increased risk of congenital malformations, particularly of cleft lip with or without cleft palate, and an increased risk of neonatal hospitalisation and death. Active management may reduce these risks, possibly through reductions in exacerbations.
Additional reassuring data have been presented for asthma medication use, which support the benefits outweighing the risks of indicated asthma medication use in pregnancy. Viral infections are an important trigger of asthma exacerbations in pregnancy, and recent data provides possible immunological changes that may explain this. Poor medication adherence despite worsening asthma symptoms in pregnancy is a problem which continues to be demonstrated in the literature. Improving asthma control in pregnancy has the potential to improve not only the mother’s health but also that of her child.
ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 3.0.